German Health Care Reform: Raising the Innovation Threshold

New reference price groups will include both patented and off-patent substances within the same class. Proving true innovation will be the only way to command premium prices. That won't be easy.

By Melanie Senior

The drug price war between health care providers and drug firms in Europe isn't new. But the battle in Germany...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo